AMGN compared with IMVT: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

IMVTImmunovant, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

IMVTImmunovant, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

IMVT: latest quarter not drawable.Method ›

Price

rebased to 0%

AMGN, solidIMVT, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only IMVT 4

ROIVRoivant Sciencessupplier

—Ypsomedunlistedsupplier

—Roivant Sciences GmbHunlistedsupplier

—

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

HanAll

unlistedsupplier

AMGNAmgen Inc

478.34· pre 479.89· delayed

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

IMVTImmunovant, Inc.

29.83· pre 30.00· delayed

Pre-marketNov 5 '26delayed

Mkt cap$6.2BRevenue—Revenue—

Compare

Pre-marketNov 5 '26delayed

AMGNAmgen Inc

IMVTImmunovant, Inc.

478.34pre 479.89delayed

Price

29.83pre 30.00delayed

$258.8B

Mkt cap

$6.2B

Q3 FY26$10.4B

Revenue

—

FY25$36.8B

Revenue

—

AMGN478.34vsIMVT29.83Pre-marketNov 5 '26delayed